Skip to main content

HARVARD BIOSCIENCE INC

For the period ended Dec 31, 2024. Filed Mar 14, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 14, 2025

HBIO$9.09+8.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

HARVARD BIOSCIENCE, INC.

TABLE OF CONTENTS

ANNUAL REPORT ON FORM 10-K

For the Year Ended December 31, 2024

INDEX

Page
PART I1
Item 1.Business1
Item 1A.Risk Factors6
Item 1B.Unresolved Staff Comments16
Item 1C.Cybersecurity17
Item 2.Properties18
Item 3.Legal Proceedings18
Item 4.Mine Safety Disclosures18
PART II18
Item 5.Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities18
Item 6.[Reserved]19
Item 7.Management's Discussion and Analysis of Financial Condition and Results of Operations19
Item 7A.Quantitative and Qualitative Disclosures about Market Risk24
Item 8.Financial Statements and Supplementary Data24
Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure24
Item 9A.Controls and Procedures24
Item 9B.Other Information28
Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections28
PART III28
Item 10.Directors, Executive Officers and Corporate Governance28
Item 11.Executive Compensation28
Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters28
Item 13.Certain Relationships and Related Transactions, and Director Independence28
Item 14.Principal Accounting Fees and Services28
PART IV28
Item 15.Exhibits and Financial Statement Schedules28
Exhibit Index
Signatures

This Annual Report on Form 10-K contains statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the“Exchange Act”). The forward-looking statements are principally, but not exclusively, contained in“Item 1: Business”* and*“Item 7: Management’s Discussion and Analysis of Financial Condition and Results of Operations.”* These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, financial performance, or achievements to be materially different from any future results, financial performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about management*’s confidence or expectations, and our plans, objectives, expectations, and intentions that are not historical facts. In some cases, you can identify forward-looking statements by terms such as “may,”* “will,” “should,” “could,” “would,” “seek,” “expects,” “plans,” “aim,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “intends,” “think,” “potential,” “objectives,” “optimistic,” “strategy,” “goals,” “sees,” “new,” “guidance,” “future,” “continue,” “drive,” “growth,” “long-term,” “projects,” “develop,” “possible,” “emerging,” “opportunity,” “pursue”and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. We discuss many of these risks in detail under the heading“Item 1A. Risk Factors” of this Annual Report on Form 10-K. Given these risks and uncertainties, you should not place undue reliance on our forward-looking statements. You should carefully review all of these factors, as well as other risks described in our public filings, and you should be aware that there may be other factors, including factors of which we are not currently aware, that could cause these differences. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information. Harvard Bioscience, Inc. is referred to herein as* “we,”* “our,” *“us,”and “the Company.”

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.